Business
Tech Stocks Underperform Despite Revenue Growth
Marvell Technology's shares fell 8% in premarket trading despite strong revenue growth, as its fiscal 2028 outlook disappointed investors. Cytokinetics' drug approval prospects may accelerate following positive trial results.
Coverage timeline — 2 articles
STAT News
It took Cytokinetics 27 years to win its first drug approval. With the results of a new trial, its second could come much faster.
2026-08-28 10:15 UTC
CNBC
Marvell Technology shares fell 8% in premarket trading despite a second-quarter revenue beat, as its fiscal 2028 outlook failed to meet investors' expectations.
2026-08-28 10:19 UTC